OptiNose Inc

NASDAQ:OPTN   11:16:21 AM EDT
1.91
0.00 (0.00%)
Other Pre-Announcement

Optinose Reports First Quarter 2022 Financial Results And Operational Updates

Published: 05/12/2022 11:16 GMT
OptiNose Inc (OPTN) - Optinose Reports First Quarter 2022 Financial Results and Operational Updates.
Q1 Revenue Rose 35 Percent to $14.8 Million.
Expects Xhance Net Revenues for Full Year of 2022 to Be at Least $90 Million.
Expects Full Year 2022 Xhance Average Net Revenue per Prescription to Be at Least $220.
Expects Top-line Results From Second of Two Clinical Trials Evaluating Xhance As a Potential Treatment for Chronic Sinusitis in June.